Loading…
Loading…
Ballast Small/Mid Cap ETF (NYSEARCA:MGMT - Get Free Report) saw a significant increase in short interest in the month of December. As of December 31st, there was short interest totaling 4,561 shares, an increase of 24.3% from the December 15th total of 3,669 shares. Approximately 0.1% of the shares of the company are sold short.
Ballast Small/Mid Cap ETF is marketed as a small/mid-cap ETF, but 70% of its components have market caps below $3 billion, making it closer to a micro-cap play. A big drawback is the MGMT's 1.10% expense ratio. Like dividends, these fees compound, making it increasingly more difficult for long-term investors to justify the extra cost. However, I'm impressed with MGMT's quality features. Ballast's screening process for management teams is qualitative, but quantitatively, it's solid too, with 14% weighted average net margins and ROE.
AGOURA HILLS, Calif., March 31, 2025 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc. (OTCQB:OTLC) (“Oncotelic,” the “Company,” or “We”), a leader in RNA-based therapeutics, today announced the publication of its latest research paper, titled, “Positive Prognostic Overall Survival Impacts of Methylated TGFB2 and MGMT in Adult Glioblastoma Patients.” The paper, authored by Sanjive Qazi, Michael Potts, Scott Myers, Stephen Richardson, and Vuong Trieu, is available online at: https://www.mdpi.com/2072-6694/17/7/1122
Small-capitalization stocks and related exchange traded funds are experiencing a great run, one that may still have legs. Among the best performing small cap ETFs of 2021, the Ballast Small/Midcap ETF (NYSE: MGMT) has increased 33.5% and the Avantis U.S. Small Cap Value ETF (AVUV) has advanced 31.3%.
Ballast Asset Management (“Ballast”), a fundamental equity manager, launched the Ballast Small/Midcap ETF (NYSE: MGMT) on Thursday. This is one of the first ETFs to trade small capitalization equities actively.